Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDEAVOR: Mitiperstat in Heart Failure with LVEF > 40%
NCT04986202Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmrEF), sponsored by AstraZeneca. Started Jun 2021; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mildly reduced ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NCT04986202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986202.